演題抄録

一般口演

開催概要
開催回
第56回・2018年・横浜
 

原発性肺腺癌におけるCD44v9の発現と意義についての検討

演題番号 : O1-2

[筆頭演者]
演者)赤嶺 貴紀:1 
[共同演者]
田川 哲三:1、伊地知 佳世:2、木下 郁彦:1、松原 太一:1、上妻 由佳:1、原武 直紀:1、髙森 信吉:1、平井 文彦:1、豊川 剛二:1、小田 義直:3、前原 喜彦:1

1:九州大学・消化器・総合外科、2:九州大学・病理病態学、3:九州大学・形態機能病理学

 

Background: CD44 isoforms serve as a marker for cancer stem cells. CD44 variant 9 (CD44v9) contributes to the defense against reactive oxygen species, resulting in resistance to chemoradiotherapy. However, the significance of the prevalence of CD44v9 in patients with lung adenocarcinoma is unknown.
Methods: We used immunohistochemical analysis to retrospectively analyze CD44v9 expression in 268 surgically resected lung adenocarcinomas and investigated the association between CD44v9 expression and patients' clinicopathological features.
Results: The expression of CD44v9 in 193 of 268 (72.0%) patients was significantly associated with early-stage cancer, low-grade tumors, absence of vessel and pleural invasion, and a mutated epidermal growth factor receptor gene. The percentage of CD44v9-positive tumors was higher in lower grade tumors and in earlier stages of disease. However, there was no significant difference in the survival of patients in each stage of disease who had positive or negative CD44v9 expression.
Conclusions: CD44v9 was highly expressed in low-grade tumors, particularly in early-stage lung adenocarcinoma, suggesting that CD44v9 expression decreases as the cancer progresses.

キーワード

臓器別:肺・縦隔・胸膜

手法別:病理

前へ戻る